LONDON–(BUSINESS WIRE)–MedEnvision (www.medenvision.com), a Belgian medtech company that helps orthopaedic surgical teams work more efficiently in the operating theatre, announces, together with its founders, management and current financial partner Smile Invest, a new strategic partnership with TA Associates (“TA”), a leading global private equity firm. TA’s investment will support MedEnvision’s long-term growth strategy, centred on continued international expansion, broadening its product p

ANTWERP, Belgium–(BUSINESS WIRE)–Regulatory News: Azelis (Brussels:AZE): Highlights Q3 2026 Revenue in the third quarter increased by 8.5% in constant currency compared to the prior year to EUR 1.1bn, driven by strong organic growth of 8.2%, supplemented by a 0.3% growth contribution from acquisitions. The organic growth acceleration drove revenue for the first nine months of the year to EUR 3.3bn, representing a year-on-year growth of 4.9%. Gross profit during the quarter was EUR 263m, repre

ANTWERPEN, België–(BUSINESS WIRE)–Koersgevoelige Informatie: Azelis (Brussels:AZE): Hoogtepunten Q3 2026 In het derde kwartaal steeg de omzet bij constante wisselkoersen met 8,5% ten opzichte van vorig jaar tot 1,1 miljard EUR, dankzij een sterke organische groei van 8,2%, aangevuld met een groeibijdrage van 0,3% uit overnames. Door de versnelling van de organische groei steeg de omzet over de eerste negen maanden van het jaar tot 3,3 miljard EUR, wat neerkomt op een groei van 4,9% tegenover

BERLIN–(BUSINESS WIRE)– #3DEXPERIENCE–Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Vertiv Holdings Co. (NYSE: VRT) today announced a collaboration to enable AI factory infrastructure to be configured, simulated and validated before construction begins. By combining Dassault Systèmes’ 3DEXPERIENCE agentic platform with Vertiv’s critical digital infrastructure expertise, the companies aim to reduce field complexity and accelerate the path from design kickoff to productive AI capacity for NVIDI

ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s

TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new operational technology (OT) security solution for industrial equipment, leveraging the world-class OT cybersecurity technologies of Nozomi Networks, Inc., a U.S.-based company that became a wholly owned subsidiary of Mitsubishi Electric in January 2026. The solution will enable industrial equipment manufacturers to implement stronger cybersecurity measures and end users to operate f

TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new operational technology (OT) security solution for industrial equipment, leveraging the world-class OT cybersecurity technologies of Nozomi Networks, Inc., a U.S.-based company that became a wholly owned subsidiary of Mitsubishi Electric in January 2026. The solution will enable industrial equipment manufacturers to implement stronger cybersecurity measures and end users to operate f

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.